Clinical trial · Observational
The iBlad App - a National, Exploratory Study on a Multimodality Smartphone App for Bladder Cancer Patients
The iBlad App - a National, Exploratory Study on a Multimodality Smartphone App in Bladder Cancer for Better Understanding of Symptoms, Quality of Life and Need for Supportive Care
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aims of this project are: * to develop and implement a national multimodality application for patients with bladder cancer that builds upon knowledge from the iBLAD study. * to investigate how the app, containing PRO questions on symptoms and QoL, information for health care providers, and peer-to-peer advice, can provide more knowledge on symptoms, QoL, and the need for supportive care. * to examine the usability of and patient satisfaction with the app using qualitative methods.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| iBLAD Application to monitor symptoms and quality of life by the use of pateint-reported outcomes | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Development and implementation of the iBLAD-app
- timeFrame
- 2 years
- description
- To develop and implement a national multimodality application (app) for patients with bladder cancer t
Secondary outcomes (2)
- measure
- App contributions
- timeFrame
- 2 years
- description
- To investigate how the app, containing PRO questions on symptoms and QoL, information for health care providers, and peer-to-peer advice, can provide more knowledge on symptoms, QoL, and the need for supportive care.
- measure
- Usability and evaluation
- timeFrame
- 2 years
- description
- To examine the usability of and patient satisfaction with the app using qualitative methods.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with bladder cancer defined as both urothelial tract-, bladder- and urethral cancer initiating first or second-line standard therapy with either chemotherapy or immunotherapy * Age ≥ 18 years, * Performance status ≤ 2 * Ability to read Danish * No serious cognitive impairment * Informed consent. Exclusion Criteria: * No smartphone, * Dementia, mental alteration, or psychiatric disease that can compromise informed consent from the patient and/or adherence to the protocol and the monitoring of the trial.
References
Publications (4)
- BACKGROUNDTaarnhoj GA, Lindberg H, Johansen C, Pappot H. Patient-Reported Outcomes, Health-Related Quality of Life, and Clinical Outcomes for Urothelial Cancer Patients Receiving Chemo- or Immunotherapy: A Real-Life Experience. J Clin Med. 2021 Apr 24;10(9):1852. doi: 10.3390/jcm10091852. PMID 33923176
- BACKGROUNDTaarnhoj GA, Johansen C, Lindberg H, Basch E, Dueck A, Pappot H. Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease. Cancer Med. 2020 May;9(9):3078-3087. doi: 10.1002/cam4.2958. Epub 2020 Mar 10. PMID 32154663
- BACKGROUNDTaarnhoj GA, Lindberg H, Dohn LH, Omland LH, Hjollund NH, Johansen C, Pappot H. Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy - a feasibility study. Health Qual Life Outcomes. 2020 Jul 11;18(1):225. doi: 10.1186/s12955-020-01480-3. PMID 32653005
- BACKGROUNDTaarnhoj GA, Lindberg H, Johansen C, Pappot H. Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy. J Patient Rep Outcomes. 2019 Aug 22;3(1):56. doi: 10.1186/s41687-019-0141-2. PMID 31440865